Microwave Ablation of Metastatic Liver and Lung Nodules in Canine Patients
Microwave Ablation is a novel therapy for noninvasive treatment of metastatic lesions of the liver or lung in dogs. Other sites will be considered on a case by case basis. This technique involves the placement of a microwave ablation probe (large needle) into the tumor via ultrasound, CT or direct surgical guidance. This is a treatment that is performed in humans for metastatic cancer.
- Inclusion Criteria: Select cases of dogs with metastatic nodules in the liver or lung.
- Initial Diagnostic Tests Required: A CT scan of the thorax (chest) and abdomen is required to determine if patients are candidates for this procedure.
- Treatment: The treatment is performed under general anesthesia. All patients will need to stay in the hospital overnight after the procedure for at least one night for observation.
- Costs: The costs of the initial work up and treatment will be discussed at the time of consultation. The cost of the microwave ablation probes are covered by the clinical trial, but the procedure costs will be the responsibility of the pet owner.
- Contact: For more information, please contact the Small Animal Hospital at 352-392-2235 to make an appointment with our oncology service for assessment. You can also email us at OncologyDept@vetmed.ufl.edu
Dr. Sarah Boston and Dr. Brad Case are the investigators in this study. You can also speak with our clinical trials coordinator at 352-294-4639 or email@example.com
In humans, microwave ablation is used as a noninvasive method of treating metastatic nodules of the liver, kidney, spleen and lungs. In this research study, we seek to use similar techniques in dogs. This approach has not previously been performed in dogs with metastatic nodules but methods have been validated in research dogs prior to use in humans.
In many cases with metastatic disease, palliative treatment is the standard of care. Dogs with liver and lung nodules due to metastatic cancer will be the primary focus of this study. Dogs with splenic nodules, renal nodules, nasal cancer and metastatic lymph nodes may also be considered for inclusion on a case-by-case basis.